Unsaturated Carbocyclic Ring Attached Directly To The Quinoline Ring System By Nonionic Bonding (e.g., Quinophthalones, Etc.) Patents (Class 546/173)
  • Patent number: 10259790
    Abstract: The present invention is directed to polymorphic forms of Pitavastatin sodium and processes for preparation of the same.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: April 16, 2019
    Assignee: LUPIN LIMITED
    Inventors: Narendra Dattatray Mane, Sagar Purushottam Nehate, Himanshu Madhav Godbole, Girij Pal Singh
  • Patent number: 9969691
    Abstract: The present invention is directed to polymorphic forms of Pitavastatin sodium and processes for preparation of the same.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: May 15, 2018
    Assignee: LUPIN LIMITED
    Inventors: Narendra Dattatray Mane, Sagar Purushottam Nehate, Himanshu Madhav Godbole, Girij Pal Singh
  • Patent number: 9434970
    Abstract: Disclosed is a method for the preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl esters, comprising the enantioselective enzyme reduction of a 1-aryl-2-tetrazolyl-ethyl ketone to form a (R)-1-aryl-2-tetrazolyl-ethyl alcohol and the carbamation of said alcohol.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: September 6, 2016
    Assignee: SK BIOPHARMACEUTICALS CO., LTD.
    Inventors: Sang Chul Lim, Moo Yong Uhm, Dae Won Lee, Hui Ho Kim, Dong Ho Lee, Hyun Seok Lee
  • Patent number: 9240553
    Abstract: The present invention provides an indeno[1,2-b]phenanthrene compound having suppressed hole transport ability. The indeno[1,2-b]phenanthrene compound represented by the general formula [1] described in claim 1 is provided. In the formula [1], R1 and R2 each represent a hydrogen atom or an alkyl group. X1 and X2 each represent a substituent selected from the group consisting of a hydrogen atom, an alkyl group, a methoxy group, and a cyano group. A1 represents a monovalent or a divalent aromatic hydrocarbon group. A2 represents a monovalent or a divalent aromatic hydrocarbon group or a monovalent or a divalent heteroaromatic group. n represents an integer of 0 to 4. When n is 2 or more, a plurality of A2 may be identical to or different from each other.
    Type: Grant
    Filed: September 10, 2013
    Date of Patent: January 19, 2016
    Assignee: Canon Kabushiki Kaisha
    Inventors: Tetsuya Kosuge, Naoki Yamada, Jun Kamatani, Kengo Kishino
  • Patent number: 9221810
    Abstract: The present invention is directed to novel substituted bicyclic aromatic compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: December 29, 2015
    Assignee: Nivalis Therapeutics, Inc.
    Inventors: Xicheng Sun, Jian Qiu, Adam Stout
  • Patent number: 9139527
    Abstract: The present invention discloses a compound, which is alkali or alkaline earth metal salts of pitavastatin, wherein the alkali or earth metal comprise one or more of magnesium, zinc, potassium, strontium and barium.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: September 22, 2015
    Assignee: Cadila Healthcare Limited
    Inventors: Shriprakash Dhar Dwivedi, Dhimant Jasubhai Patel, Alpesh Pravinchandra Shah, Brij Khera
  • Patent number: 9068207
    Abstract: Disclosed is a method for the preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl esters, comprising the enantioselective enzyme reduction of a 1-aryl-2-tetrazolyl-ethyl ketone to form a (R)-1-aryl-2-tetrazolyl-ethyl alcohol and the carbamation of said alcohol.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: June 30, 2015
    Assignee: SK BIOPHARMACEUTICALS CO. LTD.
    Inventors: Sang Chul Lim, Moo Yong Uhm, Dae Won Lee, Hui Ho Kim, Dong Ho Lee, Hyun Seok Lee
  • Publication number: 20150148360
    Abstract: The present invention provides novel compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) are inhibitors of histone deacetylases (HDACs) and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGR). Also provided are methods of using the compounds and pharmaceutical compositions for inhibiting the activity of HDACs and HMGR, treating diseases associated with HDACs or HMGR (e.g., cancer, hypercholesterolemia, an acute or chronic inflammatory disease, autoimmune disease, allergic disease, pathogen infection, neurodegenerative disease, and a disease associated with oxidative stress), or inhibiting drug resistance of cancer cells.
    Type: Application
    Filed: July 19, 2013
    Publication date: May 28, 2015
    Inventors: Jung-Hsin Lin, Jim-Min Fang, Ting-Rong Chen, Jhih-Bin Chen, Ching-Chow Chen, Tzu-Tang Wei
  • Patent number: 9034901
    Abstract: The invention provides the process for the preparation of pitavastatin and its pharmaceutically acceptable salts thereof. In particular, the invention provides a process for the preparation of stable pitavastatin calcium in crystalline form having water content less than 5% wt/wt. The present invention also provides stable crystalline form of pitavastatin calcium substantially free from crystal Form-A and use thereof for pharmaceutical compositions.
    Type: Grant
    Filed: August 24, 2011
    Date of Patent: May 19, 2015
    Assignee: Cadila Healthcare Limited
    Inventors: Shriprakash Dhar Dwivedi, Dhimant Jasubhai Patel, Alpesh Pravinchandra Shah, Brij Khera
  • Patent number: 9029392
    Abstract: Disclosed are a series of quinoline and quinoxaline derivatives comprising a fluorinated ethyl side-chain, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: May 12, 2015
    Assignee: UCB Pharma S.A.
    Inventors: Andrew Harry Parton, Mezher Hussein Ali, Daniel Christopher Brookings, Julien Alistair Brown, Daniel James Ford, Richard Jeremy Franklin, Judi Charlotte Neuss, Joanna Rachel Quincey, Jackalyn Hinkins
  • Publication number: 20150119376
    Abstract: The present invention relates to cycloalkenyl aryl derivatives, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof, or solvates thereof; a method for preparing the derivatives; and pharmaceutical compositions containing the same. The compounds of the present invention show the effect of CETP activity inhibition. It means that the compounds can increase HDL-cholesterol and decrease LDL-cholesterol.
    Type: Application
    Filed: April 12, 2012
    Publication date: April 30, 2015
    Applicant: CHONG KUN DANG PHARMACEUTICAL CORP.
    Inventors: SeoHee LEE, JungTaek OH, JaeKwang LEE, JaeWon LEE, Suyeal BAE, Nina HA, Sera LEE
  • Publication number: 20150115232
    Abstract: A chrysene-based compound and an organic light-emitting device including the same, the chrysene-based compound being represented by Formula 1, below:
    Type: Application
    Filed: April 17, 2014
    Publication date: April 30, 2015
    Applicant: SAMSUNG DISPLAY CO., LTD.
    Inventors: Kwang-Hyun KIM, Young-Kook KIM, Eun-Young LEE
  • Patent number: 9012646
    Abstract: The present invention is directed to novel substituted bicyclic aromatic compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: April 21, 2015
    Assignee: Nivalis Therapeutics, Inc.
    Inventors: Xicheng Sun, Jian Qiu, Adam Stout
  • Publication number: 20150105370
    Abstract: Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.
    Type: Application
    Filed: October 14, 2014
    Publication date: April 16, 2015
    Inventors: ERIC CARLSON, HANS HANSEN, LYNN HAWKINS, SALLY ISHIZAKA, MATTHEW MACKEY, SHAWN SCHILLER, CHIKAKO OGAWA, HEATHER DAVIS
  • Publication number: 20150105372
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    Type: Application
    Filed: October 15, 2013
    Publication date: April 16, 2015
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: KRISTI A. LEONARD, KENT BARBAY, JAMES P. EDWARDS, KEVIN D. KREUTTER, DAVID A. KUMMER, UMAR MAHAROOF, RACHEL NISHIMURA, MAUD URBANSKI, HARIHARAN VENKATESAN, AIHUA WANG, RONALD L. WOLIN, CRAIG R. WOODS, ANNE FOURIE, XIAOHUA XUE, MAXWELL D. CUMMINGS
  • Publication number: 20150105369
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    Type: Application
    Filed: October 14, 2014
    Publication date: April 16, 2015
    Inventors: KRISTI A. LEONARD, KENT BARBAY, JAMES P. EDWARDS, KEVIN D. KREUTTER, DAVID A. KUMMER, UMAR MAHAROOF, RACHEL NISHIMURA, MAUD URBANSKI, HARIHARAN VENKATESAN, AIHUA WANG, RONALD L. WOLIN, CRAIG R. WOODS, ANNE FOURIE, XIAOHUA XUE, MAXWELL D. CUMMINGS
  • Patent number: 9005778
    Abstract: There is provided a novel organic compound suitably used for a blue light-emitting device and an organic light-emitting device including the novel organic compound. The organic compound is an acephenanthryleno[4,5-k]benzo[e]acephenanthrylene derivative.
    Type: Grant
    Filed: April 19, 2011
    Date of Patent: April 14, 2015
    Assignee: Canon Kabushiki Kaisha
    Inventors: Tomonari Horikiri, Hiroyuki Tomono, Jun Kamatani
  • Publication number: 20150090967
    Abstract: A pyrene-based compound is represented by Formula 1: where R11 to R14, L11, m11, n11, k11, a12, a13, and a14 are as defined in the specification.
    Type: Application
    Filed: May 29, 2014
    Publication date: April 2, 2015
    Applicant: SAMSUNG DISPLAY CO., LTD.
    Inventors: Eun-Young LEE, Kwang-Hyun KIM, Young-Kook KIM
  • Publication number: 20150079622
    Abstract: Disclosed herein are compounds, compositions, methods, and kits for detecting reactive oxygen species (ROS) by conventional fluorescence microscopy, fluorescence spectroscopy, flow cytometry, and/or high content imaging. The compounds disclosed herein are novel reduced nucleic acid binding cyanine dyes, which dyes are probes for detecting ROS and measuring oxidative stress in cells either in vitro and/or in vivo. Also described herein are processes for preparing novel reduced dyes, i.e., ROS probes, for use in the disclosed compositions, methods and kits.
    Type: Application
    Filed: February 26, 2013
    Publication date: March 19, 2015
    Inventors: Yi-Zhen Hu, Aimei Chen, Hee Chol Kang, Kyle Gee, Bhaskar Mandavilli
  • Patent number: 8980920
    Abstract: The present invention relates to novel Linked Tricyclic Aryl Compounds, compositions comprising at least one Linked Tricyclic Compound, and methods of using Linked Tricyclic Aryl Compounds for treating or preventing HCV infection in a patient. in one aspect, the present invention provides Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein: Non-limiting examples of the Compounds of Formula (II) include compound 56.
    Type: Grant
    Filed: May 28, 2010
    Date of Patent: March 17, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Qingbei Zeng, Kevin X. Chen, Anilkumar Gopinadhan Nair, Stuart B. Rosenblum, Joseph A. Kozlowski, F. George Njoroge
  • Publication number: 20150069347
    Abstract: A condensed cyclic compound and an organic light-emitting device including the same, the condensed cyclic compound being represented by Formula 1:
    Type: Application
    Filed: June 3, 2014
    Publication date: March 12, 2015
    Applicant: SAMSUNG DISPLAY CO., LTD.
    Inventors: Kwang-Hyun KIM, Seok-Hwan HWANG, Young-Kook KIM, Jun-Ha PARK, Hye-Jin JUNG, Eun-Young LEE, Jong-Woo KIM, Jin-O LIM, Sang-Hyun HAN, Eun-Jae JEONG, Soo-Yon KIM
  • Publication number: 20150065468
    Abstract: Biaryl acetamide compounds and compositions and their methods of use are provided for modulating the activity of class III receptor tyrosine kinases and for the treatment, prevention or amelioration of one or more symptoms of disease of disorder mediated by class III receptor tyrosine kinases.
    Type: Application
    Filed: August 29, 2014
    Publication date: March 5, 2015
    Inventors: Mark W. HOLLADAY, Gang LIU, Martin W. ROWBOTTON
  • Publication number: 20150041773
    Abstract: An anthracene-based compound is represented by Formula 1 as below: wherein Ar, R1 to R3, R11 to R13, L1, L2, a1 to a3, b1, b2, n1, n2, m1, m2, o1 and o2 are as defined in the specification. An organic light-emitting device includes the anthracene-based compound.
    Type: Application
    Filed: May 21, 2014
    Publication date: February 12, 2015
    Applicant: SAMSUNG DISPLAY CO., LTD.
    Inventors: Jun-Ha PARK, Seok-Hwan HWANG, Young-Kook KIM, Hye-Jin JUNG, Eun-Young LEE, Jong-Woo KIM, Jin-O LIM, Sang-Hyun HAN, Kwang-Hyun KIM, Eun-Jae JEONG, Soo-Yon KIM
  • Patent number: 8921562
    Abstract: The present invention is directed to novel quinoline compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.
    Type: Grant
    Filed: October 7, 2011
    Date of Patent: December 30, 2014
    Assignee: N30 Pharmaceuticals, Inc.
    Inventors: Xicheng Sun, Jian Qiu, Adam Stout
  • Publication number: 20140371165
    Abstract: This disclosure features optically active stereoisomers of (2-(4-methoxy)quinolin-4-yl)(piperidin-2-yl)methanol that reduce drug resistance, compositions containing the same, and methods of using and preparing the same.
    Type: Application
    Filed: February 22, 2013
    Publication date: December 18, 2014
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Zhenfeng Duan, Francis J. Hornicek
  • Patent number: 8912333
    Abstract: The present invention provides a solid of pitavastatin tert-butyl ester and process for its preparation. The present invention also provides a novel crystalline form of pitavastatin calcium, process for its preparation and pharmaceutical compositions comprising it.
    Type: Grant
    Filed: August 23, 2011
    Date of Patent: December 16, 2014
    Assignee: Hetero Research Foundation
    Inventors: Bandi Parthasaradhi Reddy, Kura Rathnakar Reddy, Dasari Muralidhara Reddy, Samala Malla Reddy, Bandi Vamsi Krishna
  • Publication number: 20140364614
    Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.
    Type: Application
    Filed: August 26, 2014
    Publication date: December 11, 2014
    Applicant: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Paul Adriaan VAN DER SCHAAF, Fritz BLATTER, Martin SZELAGIEWICZ, Kai-Uwe SCHOENING
  • Publication number: 20140336190
    Abstract: This application relates to chemical compounds which may act as inhibitors of; or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I) wherein R1a, R1b, R2, R2b, R3, R4a, R4b, and R5 are described herein.
    Type: Application
    Filed: May 8, 2014
    Publication date: November 13, 2014
    Applicant: Gilead Sciences, Inc.
    Inventors: Evangelos Aktoudianakis, Gregory Chin, Britton Kenneth Corkey, Jinfa Du, Kristyna Elbel, Robert H. Jiang, Tetsuya Kobayashi, Rick Lee, Ruben Martinez, Samuel E. Metobo, Michael Mish, Manuel Munoz, Sophie Shevick, David Sperandio, Hai Yang, Jeff Zablocki
  • Publication number: 20140323518
    Abstract: Compounds of formula (I) or a pharmaceutically acceptable ester, amide, carbamate or salt thereof, including a salt of such an ester, amide or carbamate in which R1 to R9 have meanings as defined in the Specification, are useful as estrogen receptor ligands.
    Type: Application
    Filed: August 2, 2012
    Publication date: October 30, 2014
    Inventors: Aiping Cheng, Neeraj Garg, Lars Krüger, Joakim Löfstedt, Eva Koch, Konrad Koehler, Lars Hagberg, Daniel Nöteberg
  • Patent number: 8859108
    Abstract: An object is to provide a novel benzoxazole derivative. Another object is to reduce driving voltage of a light-emitting element. Still another object is to reduce power consumption of a light-emitting element, a light-emitting device, and an electronic device. A benzoxazole derivative represented by General Formula (G1) is provided. The benzoxazole derivative represented by General Formula (G1) has an electron-injecting property and an electron-transporting property; accordingly, it can be favorably used for a light-emitting element, a light-emitting device, and an electronic device.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: October 14, 2014
    Assignee: Semiconductor Energy Laboratory Co., Ltd.
    Inventors: Hiroshi Kadoma, Sachiko Kawakami, Takahiro Ushikubo, Satoshi Seo
  • Publication number: 20140303151
    Abstract: The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
    Type: Application
    Filed: September 14, 2011
    Publication date: October 9, 2014
    Applicant: Exelixis, Inc.
    Inventor: James William Leahy
  • Publication number: 20140303207
    Abstract: The invention provides novel 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including but not limited to depression and anxiety.
    Type: Application
    Filed: April 3, 2013
    Publication date: October 9, 2014
    Applicant: NEUROVANCE, Inc.
    Inventors: Phil SKOLNICK, Zhengming Chen
  • Patent number: 8853405
    Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.
    Type: Grant
    Filed: September 3, 2013
    Date of Patent: October 7, 2014
    Assignee: Nissan Chemical Industries Ltd.
    Inventors: Paul Adriaan Van Der Schaaf, Fritz Blatter, Martin Szelagiewicz, Kai-Uwe Schoening
  • Publication number: 20140296246
    Abstract: This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I) wherein R1a, R1b, R2a, R2b, R3, and X are described herein.
    Type: Application
    Filed: March 27, 2014
    Publication date: October 2, 2014
    Applicant: Gilead Sciences, Inc.
    Inventors: Evangelos Aktoudianakis, Gregory Chin, Britton Kenneth Corkey, Jinfa Du, Kristyna Elbel, Robert H. Jiang, Tetsuya Kobayashi, Ruben Martinez, Samuel E. Metobo, Michael R. Mish, Sophie Shevick, David Sperandio, Hai Yang, Jeff Zablocki
  • Publication number: 20140288302
    Abstract: A pharmaceutical composition including a compound of formula (I): its pharmaceutically acceptable salt, or a solvate thereof. Ring A is nitrogen-containing hetero ring, Ring A may be substituted with a substituent other than a group represented by formula: —C(R1R2)—C(?O)—NR3R4 and a group represented by formula: —R5, a broken line represents presence or absence of a bond, Z is —NR6—, ?N—, —O—, or —S—, R6 is halogen or substituted or unsubstituted alkyl, R1 and R2 are each independently hydrogen, halogen, hydroxy, cyano, nitro, carboxy or substituted or unsubstituted alkyl, R3 is hydrogen or substituted or unsubstituted alkyl, R4 is hydrogen or substituted or unsubstituted alkyl, R3 and R4 taken together with the adjacent nitrogen atom to which they are attached may form a substituted or unsubstituted ring, R5 is hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl.
    Type: Application
    Filed: March 18, 2014
    Publication date: September 25, 2014
    Applicant: Shionogi & Co., Ltd.
    Inventors: Koji MASUDA, Shiro KIDA, Kyohei HAYASHI, Manabu KATOU, Naoki YOSHIKAWA, Akira KUGIMIYA, Mado NAKAJIMA, Nobuyuki TANAKA
  • Patent number: 8829186
    Abstract: The present invention discloses a compound, which is alkali or alkaline earth metal salts of pitavastatin, wherein the alkali or earth metal comprise one or more of magnesium, zinc, potassium, strontium and barium.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: September 9, 2014
    Assignee: Cadila Healthcare Limited
    Inventors: Shriprakash Dhar Dwivedi, Dhimant Jasubhai Patel, Alpesh Pravinchandra Shah, Brij Khera
  • Publication number: 20140239269
    Abstract: A pyrene-based compound, and an organic light-emitting diode including the pyrene-based compound are provided.
    Type: Application
    Filed: August 5, 2013
    Publication date: August 28, 2014
    Inventors: Eun-Jae Jeong, Seok-Hwan Hwang, Young-Kook Kim, Hye-Jin Jung, Jun-Ha Park, Eun-Young Lee, Jin-O Lim, Sang-Hyun Han, Soo-Yon Kim, Jong-Hyuk Lee
  • Publication number: 20140228572
    Abstract: Provided are a novel chiral iridium(III) complex; and a method for producing optically active 2-substituted-1,2,3,4-tetrahydroquinolines from 2-substituted-quinolines with the use of the chiral iridium(III) complex through a more economical and easy production process.
    Type: Application
    Filed: July 13, 2012
    Publication date: August 14, 2014
    Applicant: HAMARI CHEMICALS, LTD.
    Inventors: Sadayuki Maeda, Tatsunori Sato, Yasuhiko Kawano, Toshio Miyawaki
  • Publication number: 20140209871
    Abstract: Provided is a heterocyclic compound represented by Formula 1 below and an organic light-emitting device including the heterocyclic compound of Formula 1: <Formula 1> wherein substituents in Formula 1 above are defined as in the specification.
    Type: Application
    Filed: June 26, 2013
    Publication date: July 31, 2014
    Inventors: Jun-Ha Park, Seok-Hwan Hwang, Young-Kook Kim, Hye-Jin Jung, Eun-Young Lee, Jin-O Lim, Sang-Hyun Han, Eun-Jae Jeong, Soo-Yon Kim, Jong-Hyuk Lee
  • Publication number: 20140203215
    Abstract: The present invention relates to novel materials which can be used in organic electronic devices, in particular electroluminescent devices, and are certain derivatives of fused aromatic systems.
    Type: Application
    Filed: March 19, 2014
    Publication date: July 24, 2014
    Applicant: Merck Patent GmbH
    Inventors: Holger Heil, Arne Buesing, Philipp Stoessel, Horst Vestweber
  • Patent number: 8785643
    Abstract: The present invention is directed to novel substituted bicyclic aromatic compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: July 22, 2014
    Assignee: N30 Pharmaceuticals, Inc.
    Inventors: Xicheng Sun, Jian Qiu, Adam Stout
  • Publication number: 20140191205
    Abstract: The present disclosure relates to a bipolar compound represented by the following formula (I); and an organic luminescent diode device containing the same. wherein A represents a phenyl, a biphenyl, or a terphenyl group; and Ra, Rb, and Rc are independently selected from a group consisting of a hydrogen, a halo, a cyano, a trifluoromethyl, an amino, a C1-C10 alkyl, a C2-C10 alkenyl, a C2-C10 alkynyl, a C3-C20 cycloalkyl, a C3-C20 cycloalkenyl, a C1-C20 heterocyclic alkyl, a C1-C20 hetercyclic alkenyl, an aryl, and a heteroaryl groups.
    Type: Application
    Filed: July 3, 2013
    Publication date: July 10, 2014
    Inventors: Chin-Hsien CHEN, Lun-Chia HSU, Chien-Hong CHENG
  • Publication number: 20140175402
    Abstract: The present invention provides a phosphorescent compound of one of following formulas:
    Type: Application
    Filed: November 22, 2013
    Publication date: June 26, 2014
    Applicant: LG DISPLAY CO., LTD.
    Inventor: Hyun-Cheol Jeong
  • Publication number: 20140167007
    Abstract: A pyrene-based compound and an organic light-emitting diode including the pyrene-based compound are provided.
    Type: Application
    Filed: October 8, 2013
    Publication date: June 19, 2014
    Applicant: SAMSUNG DISPLAY CO., LTD.
    Inventors: Hye-Jin Jung, Seok-Hwan Hwang, Young-Kook Kim, Jin-O Lim, Sang-Hyun Han, Eun-Jae Jeong, Soo-Yon Kim, Jun-Ha Park, Eun-Young Lee, Chang-Ho Lee, Jong-Hyuk Lee
  • Publication number: 20140148481
    Abstract: The invention provides the process for the preparation of pitavastatin and its pharmaceutically acceptable salts thereof. In particular, the invention provides a process for the preparation of stable pitavastatin calcium in crystalline form having water content less than 5% wt/wt. The present invention also provides stable crystalline form of pitavastatin calcium substantially free from crystal Form-A and use thereof for pharmaceutical compositions.
    Type: Application
    Filed: August 24, 2011
    Publication date: May 29, 2014
    Applicant: CADILA HEALTHCARE LIMITED
    Inventors: Shriprakash Dhar Dwivedi, Dhimant Jasubhai Patel, Alpesh Pravinchandra Shah, Brij Khera
  • Publication number: 20140135320
    Abstract: The present invention relates to antimalarial compounds and their use against protozoa of the genus Plasmodium, including drug-resistant Plasmodia strains. This invention further relates to compositions containing such compounds and a process for making the compounds.
    Type: Application
    Filed: November 8, 2013
    Publication date: May 15, 2014
    Applicant: Jacobus Pharmaceutical Company, Inc.
    Inventors: Gavin David Heffernan, David Penman Jacobus, Kurt William Saionz, Guy Alan Schiehser, Hong-Ming Shieh, Wenyi Zhao
  • Publication number: 20140120574
    Abstract: Nitric oxide probes comprising a compound represented by Formula I are provided. Methods of using this nitric oxide probes to detect nitric oxide are also provided.
    Type: Application
    Filed: June 4, 2013
    Publication date: May 1, 2014
    Inventors: Eric V. Anslyn, Youjun Yang, Michelle A. Ivy
  • Patent number: 8710230
    Abstract: Compounds of formula I: wherein R4, R6 and R7 are defined herein, are useful as inhibitors of HIV replication.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: April 29, 2014
    Assignee: Gilead Sciences, Inc.
    Inventors: Youla S. Tsantrizos, Murray D. Bailey, Francois Bilodeau, Rene Coulombe, Teddy Halmos, Stephen Kawai, Serge R. Landry, Steven LaPlante, Sebastien Morin, Marc-Andre Poupart, Bruno Simoneau, Lee Fader, Rebekah J. Carson, Mathieu Parisien
  • Publication number: 20140107097
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    Type: Application
    Filed: October 15, 2013
    Publication date: April 17, 2014
    Applicant: Janssen Pharmaceutica NV
    Inventors: Kristi A. Leonard, Kent Barbay, James P. Edwards, Kevin D. Kreutter, David A. Kummer, Umar Maharoof, Rachel Nishimura, Maud Urbanski, Hariharan Venkatesan, Aihua Wang, Ronald L. Wolin, Craig R. Woods, Anne Fourie, Xiaohua Xue, Taraneh Mirzadegan, Kelly Ganamet
  • Publication number: 20140107074
    Abstract: The present disclosure is directed to compounds of the structure (X): wherein: n is 2 or 3; NHE has the structure wherein: R1 is H or —SO2—NR7R8—; R2 is selected from H, —NR7(CO)R8, —SO2—NR7R8— and —NR7R8; R3 is hydrogen; R7 is hydrogen; R8 is a bond linking to L; L is a polyalkylene glycol linker; and Core has the following structure: wherein: X is selected from the group consisting of a bond, —O—, —NH—, NHC(?O)—, —NHC(?O)NH— and —NHSO2—; and Y is selected from the group consisting of a bond, optionally substituted C1-6 alkylene, optionally substituted benzene, pyridinyl, a polyethylene glycol linker and —(CH2)1-6O(CH2)1-6—, and methods of using such compounds for the treatment of irritable bowel syndrome, chronic kidney disease and end-stage renal disease.
    Type: Application
    Filed: March 14, 2013
    Publication date: April 17, 2014
    Applicant: Ardelyx, Inc.
    Inventors: Noah BELL, Christopher CARRERAS, Dominique CHARMOT, Jeffrey W. JACOBS, Michael Robert LEADBETTER, Marc NAVRE